MPI – Oncology Venture looks forward to publishing a clinical update on July 2



Hoersholm, Denmark, June 29, 2018 – Oncology Venture Sweden AB (OV:ST) and Medical Prognosis Institute A/S (MPI:ST) intends, on a quarterly basis, to publish clinical updates regarding the company’s ongoing projects and activities. Oncology Venture looks forward to publishing the first of these updates through a press release on Monday  July 2, 2018 after 12 o’clock.

About MPI’s multiple biomarker called Drug Response Predictor – DRP®
MPI’s DRP® is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP® has been tested in 37 trials, where 29 trials showed that drug-specific DRP® Biomarkers could predict which patients responded well to the treatment. The DRP® platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP® method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP® builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP® is a Big Data tool based on messenger RNA.   
The DRP® platform can be used in all cancer types and has been patented for more than 60 anti-cancer drugs in the US.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP® technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP® tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.   

For further information, please contact:
CEO, Peter Buhl Jensen, MD, PhD                              Ulla Hald Buhl, IR & Communication
E-mail: [email protected]                            E-mail: [email protected]
Telephone: +45 21 60 89 22                                         Telephone +45 21 70 10 49

Certified Adviser: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S